CompletedNCT00422123
Extended-release quetiapine for mania in bipolarity
About this title
Read the official source — NCT00422123Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Phoenix and 50 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 447
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00422123
- Official title
Show the full official title
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Mania
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix · Little Rock · Cerritos
48 more locations
- Garden Grove
- Oceanside
- Pico Rivera
- San Diego
- Santa Ana
- Torrance
- Denver
- Washington D.C.
- Aventura
- EAST Bradenton
- Fort Lauderdale
- Hollywood
- Leesburg
- Tampa
- Atlanta
- Honolulu
- Hoffman Estates
- Naperville
- OAK Brook Terrace
- Greenwood
- Indianapolis
- Newton
- Wichita
- Lake Charles
- New Orleans
- Shreveport
- Rockville
- St Louis
- Kenilworth
- Willingboro
- Elmsford
- Holliswood
- Durham
- Beachwood
- Oklahoma City
- Moon Township
- Philadelphia
- Charleston
- Memphis
- Nashville
- Austin
- DeSoto
- Houston
- Irving
- San Antonio
- Arlington
- Richmond
- Bellevue
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine fumarate (Seroquel) SR.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
